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Keratinocytes of human epidermis are actively involved
in in£ammatory and autoimmune reactions of the skin
and interact with resident or in¢ltrating immunocom-
petent cells via cytokines, chemokines, and intercellular
adhesion mechanisms. Most immunocompetent cells
have been reported to express Fcc receptors (FccR),
which are important for immunoregulatory functions.
In this study we investigate FccRIII expression on
cultured human keratinocytes and upregulation by
interferon-c. By real-time polymerase chain reaction,
we show basal mRNA expression of both subclasses
FccRIIIA and FccRIIIB, but after interferon-c treat-
ment mRNA of FccRIIIA and FccRIIIB is increased
4.4 and 6.5 times, respectively. FccRIII protein expres-
sion and its increase after interferon-c treatment were
shown on cultured human keratinocytes by indirect
immuno£uorescence. In immunoblotting experiments,
a boni¢ed anti-CD16 antibody revealed reactivity to
a polypeptide of 50^65 kDa on lysates of treated and
untreated keratinocytes. In summary, we demonstrate
expression of mRNA speci¢c for the FccRIIIA and
FccRIIIB subclasses and their upregulation by inter-
feron-c on human keratinocytes in vitro, and con¢rm
FccRIII protein expression by indirect immuno£uores-
cence and by immunoblotting experiments. Key words:
epidermal cells/Fcg receptors/real-time PCR. J Invest
Dermatol 119:1074 ^1079, 2002
K
eratinocytes are the major structural cells of the
human epidermis, but have also been shown to play
an important pathophysiologic role in in£ammatory
and immunologic processes of human skin (Stingl
et al, 1999). In£uenced by certain stimuli like aller-
gens or cytokines derived from leukocytes and monocytes, kera-
tinocytes by themselves are able to produce a wide range of
cytokines (Nickolo¡ et al, 1990; Barker et al, 1991b) and chemo-
kines (Morales et al, 1999; Traidl et al, 2000) that may activate
resident dendritic cells (Barker et al, 1991a) or contribute to
lymphocyte recruitment into the epidermis (Morales et al, 1999).
Under certain circumstances, keratinocytes may express surface
molecules necessary for interaction with T cells and leukocytes
like intercellular adhesion molecule 1 (Gri⁄ths et al, 1989) or ma-
jor histocompatibility complex class II proteins playing a key role
in the control of immune response (Albanesi et al, 1998). Immu-
nocompetent cells present in in£ammatory skin like macro-
phages, T lymphocytes, and dendritic cells express receptors
for the Fc part of IgG molecules, Fcg receptors (FcgR) (Kiekens
et al, 2000), which play an important role in immune responses as
they link the humoral immune system with cellular e¡ector
functions (Kimberly et al, 1995; Ravetch, 1997). These cell surface
glycoproteins mediate forms of phagocytosis, antibody-depen-
dent cell-mediated cytotoxicity, as well as inhibitory or activating
signal transduction (Heijnen and van de Winkel, 1997; Billadeau
and Leibson, 2002), depending on associated peptide chains or
membrane proteins involved. The leukocyte receptor family re-
presents three major classes: FcgRI (also known as CD64),
FcgRII (CD32), and FcgRIII (CD16), di¡ering in molecular
structure, binding properties, and cellular distribution (Heijnen
and van de Winkel, 1997; Ravetch, 1997). Various genes encode
subclasses of the hetero-oligomeric receptor proteins forming
transmembrane molecules, with the exception of FcgRIIIB,
which is linked to the surface membrane via its glycosylphospha-
tidylinositol (GPI) anchor (Simmons and Seed, 1988; Ravetch
and Perussia, 1989; Scallon et al, 1989). Most FcgR proteins consist
of the ligand binding a-chain with an extracellular region com-
posed of disul¢de bonded Ig-like domains (Heijnen and van de
Winkel, 1997) and form hetero-oligomeric receptor complexes
with additional subunits such as g-, z-, b-chains functioning in
FcgR assembly and, especially via their cytoplasmic tails, signal
transduction. FcgRI is a high a⁄nity receptor that binds to
monomeric and immune-complexed IgG (Ravetch and Kinet,
1991; Heijnen and van de Winkel, 1997) and is expressed on
macrophages, monocytes (Anderson, 1982; Looney et al, 1986),
interferon-g (IFN-g) alterated neutrophils (Perussia et al, 1983b),
and mast cells (Okayama et al, 2000). FcgRII is a widely distrib-
uted low a⁄nity receptor for immune complexes and found pre-
dominantly on hemopoietic cells (Mantzioris et al, 1993; Metes
et al, 1994), dendritic cells (Schmitt et al, 1990; Heijnen and van
de Winkel, 1997), and endothelial cells (Gr˛ger et al, 1996). The
FcgRIII subclasses exhibit either a low or medium a⁄nity for
monomeric or complexed IgG (Heijnen and van de Winkel,
1997) and have been shown on natural killer cells (Perussia et al,
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1983a), macrophages, monocytes (Fleit et al, 1982; Clarkson and
Ory, 1988), and granulocytes (Simmons and Seed, 1988; Ravetch,
1997).
Several reports show FcgR expression on human keratinocytes
by immuno£uorescence experiments using monoclonal antibo-
dies and soluble immune complexes (Tigalonowa et al, 1990;
1991; Bjerke et al, 1994a; 1994b). These studies suggest that FcgR
on human keratinocytes may be mediators for interaction be-
tween keratinocytes and Langerhans cells, and, in the stratum
granulosum, may contribute to the barrier function against mi-
croorganisms and various other antigens (Tigalonowa et al, 1990).
In this study, we demonstrate the presence of the subclasses
FcgRIIIA and FcgRIIIB mRNA on cultured human keratino-
cytes and their upregulation after treatment of keratinocytes with
IFN-g usingTaqMan real-time polymerase chain reaction (PCR).
Indirect immuno£uorescence with a monoclonal anti-FcgRIII
(anti-CD16) antibody revealed staining of individual keratino-
cytes. When lysates of IFN-g-treated and untreated cultured
keratinocytes were immunoblotted with the anti-CD16 anti-
body, protein expression was demonstrated by respective
antibody reactivity.
MATERIALS AND METHODS
Cell culture, antibodies, and reagents Normal human keratinocytes
were isolated from skin samples of adult skin, obtained from healthy
volunteers after cutaneous surgery. Donors gave informed consent.
Keratinocytes were grown in culture with modi¢cations, as described
previously (Boyce and Ham, 1983). Brie£y, epidermis was separated by
incubation in 50 caseolytic units per ml dispase (Collaborative, Bedford,
MA) for 1^2 h at 371C. After incubation in 0.25 mg per ml trypsin/
ethylenediamine tetraacetic acid (Clonetics, San Diego, CA) for 30 min at
371C a single cell suspension of keratinocytes was released by gentle
pipetting and cultured in keratinocyte growth medium (KGM, Clonetics,
San Diego, CA) containing 0.03 mM calcium. Normal human ¢broblasts
were isolated from skin explant cultures of de-epidermized dermis and
cultivated in Dulbecco’s modi¢ed Eagle’s medium (Gibco, Paisley,
Scotland, U.K.) containing 10% fetal bovine serum.
Cells were grown to con£uence in 100 20 mm style Petri dishes using
appropriate growth medium to obtain extracts for immunoblotting, in
eight-well chamber slides (Becton Dickinson, Franklin Lakes, NJ) for
immuno£uorescence experiments and in T-150 £asks (Techno Plastic
Products, Trasadingen, Switzerland) for mRNA isolation. Keratinocytes
and ¢broblasts were used without and after incubation with Escherichia coli
derived human recombinant IFN-g (HyCult Biotechnology, Uden, The
Netherlands; diluted in sterile distilled water to ¢nal concentration of
1000 U per ml), at a concentration of 500 U per 1,000,000 cells diluted in
culture medium, for 10 h.
For indirect immuno£uorescence and immunoblotting experiments
monoclonal antibody directed against FcgRIII (CD16), clone HuNK2,
was purchased from Neo Markers (Fremont, CA). Isotype-matched
murine control antibody (IgG2a) was from Pharmingen (Uppsala,
Sweden).
Alexa 488 conjugated goat F(ab0)2 antimouse IgG (Hþ L) from
Molecular Probes (Eugene, OR) was used as second step reagent for
indirect immuno£uorescence.
Alkaline-phosphatase-conjugated goat antimouse IgG (Promega,
Madison,WI) was used as second step antibody for immunoblotting.
Human leukocytes as positive control for immunoblotting and real-
time PCR assays were obtained from healthy volunteers and prepared
using Ficoll-Paque (Amersham Pharmacia, Biotech, Uppsala, Sweden) by
density-gradient centrifugation of heparinized venous blood, according to
a method described previously (Cassatella et al, 1990).
Quantitative real-time PCR (TaqMan) analysis Human keratino-
cytes and ¢broblasts were obtained from four di¡erent donors and
cultured separately in T-150 £asks as described above.
Con£uent keratinocytes in T-150 £asks were washed in DPBS
(Dulbecco’s Phosphate Bu¡ered Saline-0,0095 M(PO4), BioWhittaker
Europe, Verviers, Belgium), scraped from the bottom of tissue £asks, and
pelleted by centrifugation at 1600 rpm for 10 min. Cell pellets were stored
at 701C for later use. Total RNA was extracted using Qiagen RNeasy
Midi Kit (Qiagen,Valencia, CA) according to the manufacturer’s protocol
(RNeasy Midi/Maxi Handbook, ¢rst edition, October 1999, Qiagen,
Valencia, CA).
About 700 ng total RNA in solution with sterile distilled water were
reverse transcribed using TaqMan Reverse Transcription Reagents Kit
(Applied Biosystems, Foster City, CA) according to the manufacturer’s
instruction (TaqMan Universal PCR Master Mix Protocol, Applied
Biosystems). Brie£y, the reaction was performed in the presence of 10 ml
of 10TaqMan RT bu¡er, 22 ml of 25 mM magnesium chloride (5.5
mM), 20 ml deoxyNTPs mixture (500 mM of each dNTP), 5 ml of
random hexamer (2.5 mM), 2 ml of RNase inhibitor (0.4 U per ml), 2.5 ml
of MultiScribe reverse transcriptase (1.25 U per ml), and 38.5 ml of RNA
(700 ng in sterile distilled water). The ¢nal solution (100 ml) was incubated
for 10 min at 251C, another 30 min at 481C, and ¢nally for 5 min at 951C.
The resulting cDNA was stored at 701C for later use. 5 ml of cDNA
solution (about 35 ng cDNA) were used as PCR template in the presence
of 12.5 ml of TaqMan universal master mix (Applied Biosystems, Foster
City, CA), 0.5 ml (10 pmol per ml) of gene-speci¢c TaqMan probe, 2.25 ml
(10 pmol per ml) of gene-speci¢c forward and reverse primers, and 2.5 ml of
water. cDNA was also ampli¢ed in the presence of 12.5 ml TaqMan
universal master mix, 1.25 ml b-actin (Applied Biosystems, Foster City,
CA) as endogenous control, and 6.25 ml of water. Speci¢c primers and
probes for FcgRIIIA and FcgIIIB were obtained from TIB Molbiol,
Berlin, Germany. The sequences for primers and probes used for cDNA
ampli¢cation were designated using Primer Express 1.0 software (supplied
by Applied Biosystems) with DNA and the appropriate mRNA sequence
of FcgRIIIA and FcgRIIIB gene (Peltz et al, 1989; Gessner et al, 1995) from
Entrez Nucleotide’s search tool on the World WideWeb (National Center
of Biotechnology Information (NCBI), Bethesda, MD: http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db=Nucleotide). The following primers
were used:TGGCATGCGGACTGAAGAT (forward) and AAGCACGCT-
GTACCATTGAGG (reverse) for FcgRIIIA; and TGGCATGCGGACTGA-
AGA (forward) and AAGCACGCTGTACCATTGAGG (reverse) for
FcgRIIIB. The sequences for speci¢c £uorogenic probes were TCCCAAA-
GGCTGTGGTGTTCCTGGT for FcgRIIIA and CCCAAAGGCTGTGG-
TGTTCCTGGA for FcgRIIIB. The speci¢city of the chosen primers was
tested using NCBI BLAST Search Database to exclude possible cross-
reactivity with genomic DNA. Gene-speci¢c probes were labeled with
FAM as reporter whereas the probe for endogenous control was VIC
associated. The samples underwent the following stages: stage 1, 501C for
2 min; stage 2, 951C for 10 min; stage 3, 951C for 15 s followed by 601C for
1 min. Stage 3 was repeated 45 times. Gene-speci¢c products were
measured by means of an ABI PRISM 7700 Sequence Detection System
(Perkin-Elmer Applied Biosystems, Foster City, CA) continuously during
45 cycles.
Relative quanti¢cation of mRNA expression was performed according
to the manufacturer’s protocol using the comparative CT (threshold cycle)
method (User Bulletin ABI PRISM 7700 Sequence Detection System).
The relative quantity of mRNA FcgRIIIA and FcgIIIB in IFN-g-treated
cells is given by 2DDCT, where DDCT¼mean DCT (mRNA from treated
cells) ^mean DCT calibrator (mRNA from untreated cells). Mean DCT is
the average DCT value of four di¡erent donors. CT of b-actin subtracted
from gene-speci¢c CT gives the DCT for each donor.
For control RNA from human leukocytes (four di¡erent donors),
untreated and IFN-g-treated ¢broblasts were extracted and reverse
transcribed, and cDNAwas used for ampli¢cation with the same primers
and probes as described above for keratinocytes. Statistical analysis
was performed using the paired Student’s t test, and p-values o0.05
were considered as statistically signi¢cant. Variables are described by
mean7standard deviation.
Cell proliferation and cytotoxicity assay To determine the cytotoxic
e¡ects of IFN-g on cultured human keratinocytes in vitro a nonradioactive
cell proliferation and cytotoxicity assay (Biomedica, Vienna, Austria) was
performed (Mosmann, 1983). For this purpose, keratinocytes were grown
to con£uence and incubated with human recombinant IFN-g (500 U for
1,000,000 cells) for 10 h in 96-well plates. Lyophilized dye substrate
solution was dissolved in activator solution and warmed up to 371C prior
to use. 20 ml of this solution was then added to each well containing 200 ml
KGM and incubated 4 h at 371C. The plate was mixed and the absorbance
was read at 450 nm with 630 nm as reference. The metabolic capacity of
cells is a result of their ability to convert the yellow-colored tetrazolium
compound to its red formazan derivate. The reference absorbance at
630 nm is used to correct for nonspeci¢c background values. Absorbance
from a substrate blank in assay medium without cells was subtracted from
all values.
Indirect immuno£uorescence on cultured cells Normal human
keratinocytes were grown to near con£uence in eight-well chamber slides,
¢xed with 3% paraformaldehyde for 30 min, and incubated with mouse
monoclonal anti-CD16 antibody (Neo Markers, clone HuNK2), diluted
1:50 in PBS, for 1 h. The cells were then washed with PBS and incubated
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in appropriate second step antibody, diluted 1:100 in PBS, for 1 h, followed
by ¢nal washing and embedding in £uoprep (bioMeŁ rieux, Marcy I’Etoile,
France). Alternatively, keratinocytes were incubated with IFN-g for 10 h
(HyCult Biotechnology; 1000 U per ml stock solution; 500 U per
1,000,000 cells) and ¢xed, and immuno£uorescence was performed.
Human ¢broblasts were cultured in appropriate medium in eight-well
chamber slides, ¢xed with 3% paraformaldehyde for 30 min, incubated
with anti-CD16 antibody (Neo Markers, clone HuNK2, diluted 1:50 in
PBS), washed, and incubated with the respective second step antibody. The
same procedure was also performed with IFN-g-treated ¢broblasts (10 h).
Embedded cells were examined using an OLYMPUS BH 2-RFCA
£uorescence microscope.
Immunoblotting Immunoblotting was performed according to
methods described previously (Hashimoto et al, 1990). Keratinocytes were
grown to con£uence in Petri dishes. A portion was treated with human
IFN-g (HyCult Biotechnology; 1000 U per ml stock solution; 500 U per
1,000,000 cells) for 10 h. After washing in PBS, cells were scraped from
the Petri dish into a 1.5 ml Eppendorf tube (Eppendorf-Netheler-Hinz,
Hamburg, Germany), homogenized in 2% sodium dodecyl sulfate (SDS,
Bio-Rad, Hercules, CA) in 0.0625 M Tris-bu¡ered saline, pH 6.8,
supplemented with 5% 2-mercaptoethanol (Bio-Rad, Hercules, CA) and
2 mM phenymethylsulfonyl £uoride (Sigma Chemical, St. Louis, CA),
boiled, and centrifuged. Alternatively, cultured human ¢broblasts, with
and without IFN-g treatment, and normal human leukocytes were lyzed
accordingly. Extracted proteins were separated by SDS polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose
membranes (Towbin et al, 1979). Strips of nitrocellulose were exposed to
mouse monoclonal anti-CD16 antibody (Neo Markers, clone HuNK2) or
isotype control antibody (Pharmingen), each diluted 1:20 in blotting bu¡er
overnight, washed, and incubated with alkaline-phosphatase-conjugated
goat antimouse IgG (Promega). Bound antibody was visualized by
nitroblue tetrazolium/bromochloroindolyl phosphatase (Kirkegaard and
Perry Laboratories, Gaithersburg, MD) enzyme reaction (Blake et al, 1984).
RESULTS
FccRIIIA and FccRIIIB mRNA expression in cultured
human keratinocytes is upregulated by IFN-c To demons-
trate unalterated viability of IFN-g-treated cultured keratino-
cytes and ¢broblasts, a nonradioactive cell proliferation and
cytotoxicity assay was performed. The cells exhibited no altered
metabolic capacity, untreated or after treatment with IFN-g
for 10 h at the concentrations described (data not shown).
We performed real-time PCR experiments to investigate the
mRNA expression of FcgRIII in cultured human keratinocytes
and to determine possible upregulation of the two heteromeric
isoforms FcgRIIIA and FcgRIIIB after IFN-g treatment using
speci¢c primers and probes to distinguish FcgRIIIA and
FcgRIIIB transcripts. TaqMan real-time PCR assay is based on
measuring threshold cycle (CT) values associated with the
increase of detection signal indicating exponential growth of the
PCR product. b-Actin was used as endogenous control. Using
the comparative CT method we obtained the relative quantity of
upregulated mRNA (Tables I, II). CT mRNA values of
FcgRIIIA and b-actin from untreated and IFN-g-treated
keratinocytes of four di¡erent donors were measured and used
to determine the relative quantity of FcgRIIIA mRNA. Based
on this calculation, cultured human keratinocytes treated with
IFN-g resulted in about a 4.4 -fold higher expression of FcgIIIA
mRNA compared with that of untreated keratinocytes (Table I).
The relative quantity of FcgRIIIB mRNA is determined by
measured CT mRNA values of FcgRIIIB and b-actin from
untreated and IFN-g-treated keratinocytes. As a result, the
expression of FcgRIIIB mRNA is about 6.5-fold higher in
treated than in untreated keratinocytes (Table II).
Upregulation of FcgRIIIA and FcgRIIIB mRNA after
treatment with human IFN-g was signi¢cant when a paired
Student’s t test was performed (p-values: 0.024 for FcgRIIIA and
0.022 for FcgRIIIB). RNA from human leukocytes obtained
from four healthy volunteers was used as positive control. The
leukocytes contained 5595 times as much FcgRIIIA mRNA and
1217 times as much FcgRIIIB mRNA compared to untreated
human keratinocytes (data not shown). In contrast, mRNA
isolated from cultured IFN-g-treated and untreated human
¢broblasts after reverse transcription was used for real-time
PCR analysis. In 45 performed cycles we could not detect
speci¢c cDNA amp£ication, either in untreated or in treated
Table I. FcgRIIIA mRNA expression and upregulation with IFN-g in human keratinocytes

















2DDCT ¼ relative quantity
of upregulated mRNA
Donor 1 34.90 19.16 15.74 33.87 21.14 12.73
Donor 2 33.36 19.23 14.13 32.95 20.24 12.71
Donor 3 33.18 18.99 14.19 33.50 20.43 13.07
Donor 4 37.71 20.27 17.44 34.56 20.10 14.46
15.3871.57 13.2470.83 ^2.1470.83 4.41 (2.48^7.84)
aCT, threshold cycle.
bDDCT¼mean DCT (mRNA of treated cells)mean DCT calibrator (mRNA of untreated cells).
cDCT¼CT FcgRIIIACT b-actin.
Table II. FcgRIIIB mRNA expression and upregulation with IFN-g in human keratinocytes

















2DDCT ¼ relative quantity
of upregulated mRNA
Donor 1 35.24 19.16 16.08 34.94 21.14 13.80
Donor 2 33.61 19.23 14.38 33.46 20.24 13.22
Donor 3 34.00 18.99 15.01 32.83 21.69 11.14
Donor 4 40.76 20.27 20.49 35.10 18.13 16.97
16.4972.76 13.7872.41 ^2.7172.41 6.54 (1.23^34.78)
aCT, threshold cycle.
bDDCT¼mean DCT (mRNA of treated cells)mean DCT calibrator (mRNA of untreated cells).
cDCT¼CT FcgRIIIBCTb-actin.
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¢broblasts, indicating that human ¢broblasts do not express
FcgRIIIA and FcgRIIIB mRNA.
Indirect immuno£uorescence shows FccRIII protein expres-
sion on cultured human keratinocytes Indirect immuno£uo-
rescence was performed on cultured human keratinocytes to
examine protein expression of FcgRIII molecules. Using a
mouse monoclonal antibody directed against FcgRIII we found
a weak but distinct granular £uorescence staining pattern with
individual keratinocytes (Fig 1a). We also tested IFN-g-treated
(10 h, 500 U per 1,000,000 cells) keratinocytes. In that case, the
£uorescence staining from individual keratinocytes gave a
speci¢c and distinct granular pattern (Fig 1b).
Biochemical characterization shows FccRIII protein
expression on cultured human keratinocytes We examined
the speci¢city of FcgRIII protein expression on cultured human
keratinocytes by immunoblotting experiments. Protein lysates
were prepared from cultured human keratinocytes without and
after 10 h treatment with IFN-g. The extracted proteins were
separated electrophoretically and transferred to nitrocellulose.
Strips of the blotted proteins were incubated with the mono-
clonal antibody against FcgRIII. When untreated keratinocytes
were probed, weak binding reactivity of the antibody to a
polypeptide at 50^65 kDa (Fig 2, lane 1) was observed. Lysates
obtained from keratinocytes after 10 h treatment with IFN-g
were immunoblotted with the same antibody and gave
prominent reactivity with the polypeptide of 50^65 kDa indi-
cating a selective increase of protein expression (Fig 2, lane 2).
For control, immunoblotting with the anti-FcgRIII antibody
was performed on SDS lysates from human leukocytes giving
same reactivity (Fig 2, lane 3). When protein extracts of
¢broblasts with and without IFN-g treatment were used for
immunoblotting, no reactivity could be detected (Fig 2, lanes 4, 5).
DISCUSSION
In this study, we demonstrate that cultured human keratinocytes
express FcgRIIIA and FcgRIIIB genes and FcgRIII protein on
their cell surface. As FcgRIII is encoded by two homologous
genes (Peltz et al, 1989; Gessner et al, 1995), we performed real-time
PCR experiments using speci¢c primers and probes for
FcgRIIIA and FcgRIIIB, to characterize subtypes and also to
show the possible induction of gene expression by treatment
with IFN-g. Normal human keratinocytes cultured in selective
keratinocyte growth medium show mRNA expression of both
isoforms, at a relative low level, however, compared to human
leukocyte mRNA, which was used as positive control.
IFN-g, a multifunctional lymphokine secreted by T lympho-
cytes, natural killer cells, and Langerhans cells, is known to act
as a potent stimulus for keratinocytes (Barker et al, 1990; Nickolo¡
et al, 1990; Kalvakolanu and Borden, 1996). According to previous
reports on IFN-g upregulation of FcgRIII proteins on neutro-
phils (Ravetch and Perussia, 1989) and eosinophils (Hartnell et al,
1992), we asked whether these molecules can be upregulated by
IFN-g in cultured human keratinocytes. As it has been reported
that IFN-g induces growth arrest and cell di¡erentiation in
epithelial cells within 12 h of treatment (Saunders et al, 1996), we
incubated the cells for 10 h with IFN-g and performed additional
cell cytotoxicity assays. Real-time PCR results showed that gene
expression on human keratinocytes was altered by incubation
with IFN-g. The FcgRIIIA expression was 4.4 -fold higher and
FcgRIIIB was 6.5-fold higher after treatment with IFN-g. This
upregulation is still much lower than reported for FcgRI and
FcgRIII on human mast cells or neutrophils (Perussia et al,
1983b; Okayama et al, 2000), and eosinophils (Hartnell et al, 1992),
respectively.
Immuno£uorescence experiments with monoclonal antibodies
against known structural epitopes exhibited the presence of
FcgRIII protein on cultured human keratinocytes. After treat-
ment with human recombinant IFN-g there was a marked in-
crease in intensity in the form of a granular £uorescence signal
on individual keratinocytes indicating upregulated FcgRIII pro-
tein expression at the light microscopy level.These ¢ndings could
be observed on ¢xed as well as freshly prepared keratinocytes
(not shown). Immunoblotting lysates of IFN-g-treated and un-
treated cultured keratinocytes using the boni¢ed anti-CD16 anti-
body yielded reactivity with a polypeptide of 50^65 kDa
appearing as a broad band. The reactivity on untreated keratino-
cytes was low, however, giving a weak band at the expected mo-
lecular weight. It is interesting to note that the £uorescence
pattern resembles surface binding of immune complexes on ker-
atinocytes as described previously (Tigalonowa et al, 1991). The
molecular weight of the polypeptide corresponds to that recog-
nized by the anti-CD16 antibody in lysates of keratinocytes as
Figure1. Indirect immuno£uorescence on cultured human kerati-
nocytes exhibits expression of FccRIII. Con£uent keratinocytes were
¢xed with 3% paraformaldehyde, exposed to mouse monoclonal anti-
CD16 antibody and Alexa 488 conjugated second step reagent. At the cell
surface of untreated cultured human keratinocytes, FcgRIII expression
could be detected as a weak granular staining pattern (a).When keratino-
cytes were treated with IFN-g for 10 h prior to ¢xation and immuno£uor-
escence with anti-CD16 antibody, a strong, distinct granular staining
pattern demonstrates signi¢cant upregulation of FcgRIII on the cell surface
of keratinocytes. Scale bar: 20 mm.
Figure 2. Biochemical detection of FccRIII on cultured human
keratinocytes. Protein lysates of cultured human keratinocytes and ¢bro-
blasts and, for control, peripheral blood leukocytes were separated by SDS-
PAGE followed by transfer onto nitrocellulose. Lane 1 shows immunoblot-
ting with monoclonal anti-CD16 antibody using untreated keratinocytes
giving reactivity at 50^65 kDa. When keratinocytes were treated with
IFN-g for 10 h before protein preparation, immunoblotting with anti-
CD16 antibody gave a more prominent reaction at 50^65 kDa as shown
in lane 2. This reaction is similar to the labeling of anti-CD16 on blood
leukocytes in lane 3. No speci¢c reaction was observed when untreated, lane
4, and IFN-g-treated human ¢broblasts, lane 5, were used. Immunoblotting
with isotype control antibody (mouse IgG2a) on keratinocytes, lane 6,
leukocytes, lane 7, and ¢broblasts, lane 8, gave no binding.
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found when anti-CD16 antibody was reacted with the leuko-
cyte lysates. These ¢ndings let us assume that cultured human
keratinocytes express the entire functional heteromeric FcgRIII
molecule.
The subclasses of human FcgRIII are encoded by two linked
genes: a transmembrane form (IIIA) with a 25 amino acid cyto-
plasmic tail and a GPI-linked form (IIIB) without a cytoplasmic
portion (Simmons and Seed, 1988; Ravetch and Perussia, 1989).
The multichain transmembranous FcgRIIIA is one of those re-
ceptors with an immunoreceptor tyrosine-based activation motif
(ITAM; Billadeau and Leibson, 2002) mediating cell activation,
endocytosis, and phagocytosis. FcgRIIIB, a human receptor
without ITAM, has no triggering capability by itself but appears
to transduce signals with additive receptor proteins like FcgRIIA
(Vossebeld et al, 1995; Heijnen and van de Winkel, 1997). The
FcgRIIIA displays medium a⁄nity interacting with monomeric
and complexed IgG and is predominantly expressed on natural
killer cells (Perussia et al, 1983a), macrophages, and monocytes
(Fleit et al, 1982; Clarkson and Ory, 1988), whereas FcgRIIIB
serves for ligand binding on neutrophils (Ravetch and Perussia,
1989).
In our study we provide molecular biologic, immunomorpho-
logic, and biochemical evidence that human keratinocytes express
FcgRIII, which appears to be signi¢cantly upregulated by IFN-g.
Using real-time PCR, we could also observe gene expression for
FcgRI and FcgRII subtypes at a low level, with no signi¢cant
upregulation (data not shown). Human FcgR represent a family
of cell surface glycoproteins known to mediate interactions of
IgG antibodies with immune e¡ector cells to generate and con-
trol an appropriate humoral immune response (Heijnen and van
deWinkel, 1997). As most immunocompetent cells express multi-
ple FcgR, each of the expressed proteins acts in concert with the
other FcgR families expressed on the same cell. Depending on
the cell type or on cytokines that di¡erentially regulate the
expression of various FcgR, and the composition of immune
complexes they interact with, the FcgR elicit respective immuno-
regulatory processes (Daeron, 1997).
Only few reports have shown protein expression of FcgR mo-
lecules on human keratinocytes (Tigalonowa et al, 1990; 1991;
Bjerke et al, 1994a; 1994b). Their expression on human keratino-
cytes can still be said to be a matter of controversy. In view of
the potentially important immunomodulatory role of keratino-
cytes in human epidermis, we searched for the presence and in-
vestigated the possible upregulation of FcgR molecules at the
mRNA and protein level. FcgRIII has been reported to be in-
volved in immune complex mediated in£ammation binding to
complex and weak monomeric IgG. Mice de¢cient for the a-
chain of FcgRIII lack natural-killer-cell-mediated antibody-de-
pendent cytotoxicity and phagocytosis and exhibit an impaired
Arthus reaction (Hazenbos et al, 1996), indicating that the class
III receptor plays a prominent role in type III in£ammatory re-
sponse. Although FcgR deliver signals when aggregated at the
cell surface and low and medium a⁄nity receptors do not bind
monomeric immunoglobulins with a measurable a⁄nity (Daer-
on, 1997), it is possible that human keratinocytes are actively in-
volved in immunoregulatory procedures via their FcgRIII. For
example, lupus erythematosus, an autoimmune disease with skin
involvement, is caused by immune complexes and characterized
by autoantibodies directed against intracellular target molecules
(Sontheimer, 1999; Kamradt and Mitchison, 2001). Studies with
antinuclear antibodies of patients with systemic lupus erythema-
tosus have suggested that autoantibodies might enter the cells via
FcgR (Alarco¤ n-Segovia et al, 1979). Considering that these auto-
antibodies are also targeting intracellularly located antigens in
keratinocytes, one could imagine that under certain conditions
FcgR are involved in the penetration of antibodies into cells. Like
GPI-linked FcgRIIIB, various proteins have been reported to be
anchored in GPI-rich plasma membrane domains like, for exam-
ple, caveolin 1 (Rothberg et al, 1992), the protein component of
caveolae, small plasmalemmal vesicles involved in clathrin-inde-
pendent endocytosis. Interaction among those proteins could
help antibodies or other molecules to reach the interior of cells
via receptor-mediated endocytosis. Moreover, FcgRIIIA has been
shown to mediate endocytosis (Strzelecka et al, 1997; Hunter et al,
1998), leading to the hypothesis that both subclasses could sup-
port ligand binding and elicit cellular pathways initializing
FcgR-mediated endocytosis via plasmalemmal vesicles. As the
nature of a response to FcgR depends primarily on the cell type
(Daeron, 1997) one can imagine that FcgR proteins contribute to
the immunoregulatory functions of keratinocytes eliciting ligand
binding and cell signaling in a cell-speci¢c fashion. Based on our
data, the level of FcgRIII expression on human keratinocytes is
much lower than its expression on human leukocytes. But IFN-
g treatment induced signi¢cant upregulation of FcgRIII on cul-
tured human keratinocytes. So it might be possible that func-
tional FcgRIII contributes to the immunoregulatory capacity of
keratinocytes in activating signal transduction and cytokine pro-
duction in the course of in£ammatory and immunologic pro-
cesses of skin diseases (Barker et al, 1991a; Heijnen and van de
Winkel, 1997), though its role remains to be clari¢ed.
In summary, we demonstrate expression of FcgRIIIA and
FcgRIIIB mRNA in cultured human keratinocytes and its upre-
gulation by IFN-g. Immuno£uorescence and immunoblotting
results suggest expression of functional FcgRIII proteins reactive
to IFN-g stimulation. Further in vitro and in vivo studies are neces-
sary to elucidate the functional relevance of FcgR expression by
human keratinocytes.
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